Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids : Previous strategies, recent advances and key factors description
Copyright © 2023 Elsevier B.V. All rights reserved..
In view of the strong anti-inflammatory activity of glucocorticoids (GC) they are used in the treatment of almost all inflammatory lung diseases. In particular, inhaled GC (IGC) allow high drug concentrations to be deposited in the lung and may reduce the incidence of adverse effects associated with systemic administration. However, rapid absorption through the highly absorbent surface of the lung epithelium may limit the success of localized therapy. Therefore, inhalation of GC incorporated into nanocarriers is a possible approach to overcome this drawback. In particular, lipid nanocarriers, which showed high pulmonary biocompatibility and are well known in the pharmaceutical industry, have the best prospects for pulmonary delivery of GC by inhalation. This review provides an overview of the pre-clinical applications of inhaled GC-lipid nanocarriers based on several key factors that will determine the efficiency of local pulmonary GC delivery: 1) stability to nebulization, 2) deposition profile in the lungs, 3) mucociliary clearance, 4) selective accumulation in target cells, 5) residence time in the lung and systemic absorption and 6) biocompatibility. Finally, novel preclinical pulmonary models for inflammatory lung diseases are also discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:642 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 642(2023) vom: 25. Juli, Seite 123146 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Altube, María Julia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug Carriers |
|---|
| Anmerkungen: |
Date Completed 24.07.2023 Date Revised 24.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2023.123146 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358317185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358317185 | ||
| 003 | DE-627 | ||
| 005 | 20231226074502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2023.123146 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358317185 | ||
| 035 | |a (NLM)37330156 | ||
| 035 | |a (PII)S0378-5173(23)00566-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Altube, María Julia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids |b Previous strategies, recent advances and key factors description |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2023 | ||
| 500 | |a Date Revised 24.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a In view of the strong anti-inflammatory activity of glucocorticoids (GC) they are used in the treatment of almost all inflammatory lung diseases. In particular, inhaled GC (IGC) allow high drug concentrations to be deposited in the lung and may reduce the incidence of adverse effects associated with systemic administration. However, rapid absorption through the highly absorbent surface of the lung epithelium may limit the success of localized therapy. Therefore, inhalation of GC incorporated into nanocarriers is a possible approach to overcome this drawback. In particular, lipid nanocarriers, which showed high pulmonary biocompatibility and are well known in the pharmaceutical industry, have the best prospects for pulmonary delivery of GC by inhalation. This review provides an overview of the pre-clinical applications of inhaled GC-lipid nanocarriers based on several key factors that will determine the efficiency of local pulmonary GC delivery: 1) stability to nebulization, 2) deposition profile in the lungs, 3) mucociliary clearance, 4) selective accumulation in target cells, 5) residence time in the lung and systemic absorption and 6) biocompatibility. Finally, novel preclinical pulmonary models for inflammatory lung diseases are also discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Inflammatory lung diseases | |
| 650 | 4 | |a Liposomes | |
| 650 | 4 | |a Nanostructured lipid carriers | |
| 650 | 4 | |a Nebulization | |
| 650 | 4 | |a Solid lipid nanoparticles | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Perez, Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Eder Lilia |e verfasserin |4 aut | |
| 700 | 1 | |a Morilla, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Higa, Leticia Herminia |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Ana Paula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 642(2023) vom: 25. Juli, Seite 123146 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:642 |g year:2023 |g day:25 |g month:07 |g pages:123146 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2023.123146 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 642 |j 2023 |b 25 |c 07 |h 123146 | ||